Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Valeant Pharmaceuticals Intl (VRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,382,198
  • Shares Outstanding, K 349,300
  • Annual Sales, $ 8,724 M
  • Annual Income, $ 2,404 M
  • 36-Month Beta -0.34
  • Price/Sales 1.07
  • Price/Cash Flow 2.06
  • Price/Book 1.99

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.38 +17.88%
on 05/29/18
27.79 -9.31%
on 06/13/18
+3.06 (+13.84%)
since 05/18/18
3-Month
14.95 +68.53%
on 04/02/18
27.79 -9.31%
on 06/13/18
+8.47 (+50.65%)
since 03/16/18
52-Week
10.94 +130.38%
on 11/02/17
27.79 -9.31%
on 06/13/18
+12.54 (+99.08%)
since 06/16/17

Most Recent Stories

More News
FDA Issues Complete Response Letter For DUOBRII(TM) (Halobetasol Propionate and Tazarotene) Lotion

Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX), today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration...

VRX.TO : 33.07 (-6.77%)
VRX : 25.09 (-6.59%)
Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

CELG : 77.42 (-0.85%)
LCI : 14.90 (-6.29%)
GILD : 69.52 (-1.01%)
VRX : 25.09 (-6.59%)
BIIB : 287.47 (-5.76%)
Bausch + Lomb Launches Soothe® Xtra Protection Preservative Free Lubricant Eye Drops

Now Available at Major U.S. Retailers

VRX.TO : 33.07 (-6.77%)
VRX : 25.09 (-6.59%)
Drug Stocks: The Next Hot Industry or Value Traps?

These 5 stocks look dirt cheap but is it too good to be true?

CELG : 77.42 (-0.85%)
LCI : 14.90 (-6.29%)
GILD : 69.52 (-1.01%)
VRX : 25.09 (-6.59%)
BIIB : 287.47 (-5.76%)
Bausch + Lomb Introduces Ocuvite® Blue Light Eye Vitamins

Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International (NYSE/TSX: VRX), today announced the introduction of Ocuvite(®) Blue Light eye vitamins,...

VRX.TO : 33.07 (-6.77%)
VRX : 25.09 (-6.59%)
Today's Research Reports on Trending Tickers: Valeant Pharmaceuticals and OPKO Health

NEW YORK, NY / ACCESSWIRE / June 11, 2018 / U.S. markets finished higher and logged strongest week in months as investors shrug off tensions between U.S. and its allies. The Dow Jones Industrial Average...

OPK : 4.47 (+1.59%)
VRX : 25.09 (-6.59%)
Securities Class Action Filed on Behalf of Persons or Entities That Traded Certain Derivative Securities of Valeant Pharmaceuticals International, Inc. During the Period January 4, 2013 Through August 11, 2016, Inclusive

Entwistle & Cappucci LLP ("Entwistle & Cappucci") today announced that it has filed a securities class action lawsuit on behalf of persons or entities that purchased call options and/or sold...

VRX.TO : 33.07 (-6.77%)
VRX : 25.09 (-6.59%)
Valeant (VRX) Up 19.3% Since Earnings Report: Can It Continue?

Valeant (VRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

VRX : 25.09 (-6.59%)
Detailed Research: Economic Perspectives on Central European Media Enterprises, Valeant Pharmaceuticals International, Nice, NCS Multistage, NewLink Genetics, and Colliers International Group -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Central European Media Enterprises...

VRX.TO : 33.07 (-6.77%)
CIGI : 73.35 (+1.38%)
NICE : 110.78 (+1.34%)
CETV : 3.95 (unch)
NCSM : 13.18 (+0.46%)
VRX : 25.09 (-6.59%)
NLNK : 5.31 (-0.75%)
Valeant Announces Closing Of Amended And Restated Credit Agreement Transaction And Senior Notes Offering, As Well As Redemption Of Existing Senior Notes

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that it has entered into a Fourth Amended & Restated Credit and Guaranty Agreement (the "New Credit...

VRX.TO : 33.07 (-6.77%)
BK : 56.81 (-0.21%)
VRX : 25.09 (-6.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade VRX with:

Business Summary

Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients....

See More

Key Turning Points

2nd Resistance Point 27.35
1st Resistance Point 27.10
Last Price 25.08
1st Support Level 26.62
2nd Support Level 26.39

See More

52-Week High 27.79
Last Price 25.08
Fibonacci 61.8% 21.35
Fibonacci 50% 19.36
Fibonacci 38.2% 17.38
52-Week Low 10.94

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar